Takeda, BioNumerik drop licensing pact

Takeda and San Antonio-based BioNumerik Pharmaceuticals have terminated their licensing deal for an experimental neuropathy drug. The move to separate came after Tavocept failed two Phase III trials to treat neuropathy in cancer patients earlier this year.

- here's the release on the un-deal

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.